JIUNN-LIANG KO2026-10-162026-10-162014-10-01Pure ID: 15453977Pure UUID: 559fa362-1b80-43b3-88aa-f219c31292a0https://www.scopus.com/pages/publications/84917725833https://scholars.csmu.edu.tw/handle/123456789/30988Background: Sequential treatments using various targeted-therapies have been recommended for metastatic renal cell carcinoma. However, regimen selection remains difficult when adapting to various clinical situations. Patients and Methods: From 2006 to 2012, 29 patients who received sequential targeted-therapy at our hospital were included for analysis of the treatment regimens and outcome. Results: Patients who used sunitinib as first-line and axitinib as second-line treatment experienced a similar second-line treatment duration, as those used the same first-line and everolimus as the secondline regimen. The first-line sunitinib treatment duration was longer in the axitinib group. Conclusion: Our data showed a promising sequential treatment result using sunitinibaxitinib and sunitinib-everolimus. In patients whose firstline sunitinib treatment resulted in primary resistance, second-line everolimus was found to still contribute a fair degree of disease control. Patients who responded to first-line sunitinib could also achieved fair disease control using second-line axitinib.5enjournal article